The BOSS device delivers RF energy simultaneously with saline, which can reduce operating time and improve post-operative outcomes, to perform coagulation of soft tissue and bone, resulting in reduced blood loss while minimizing charring and sticking of tissue, according to the release.
Marketing of the BOSS will primarily be targeted to orthopedic surgeons performing hip and knee arthroplasty, which represent large and growing markets due to a more active and aging population, according to the release. Bovie also plans to expand marketing to spine, endoscopic, abdominal and thoracic surgery markets.
Read the release on the Bovie BOSS coagulation device.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
